NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET 2019-2027

Lifesciences | Diagnostic & Biotechnology

NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET 2019-2027

Market By Gender, End-use And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Research conducted by Triton shows that the North America infertility (testing and treatment) market is expected to grow at a CAGR of 6.83% over the forecasting period of 2019-2027.

North America infertility (testing and treatment) market report analyze major countries such as:

•           United States

•           Canada

Infertility is a condition in which a couple is unable to conceive progeny. Usually, couples who have been attempting to conceive without any success by engaging in regular sexual intercourse without the use of contraception are diagnosed with infertility. Infertility could be caused to one of the partner’s inability to contribute to conception, or the woman’s inability to carry a pregnancy to its full term.

Triton has discussed in detail, the market definition, key insights, market attractiveness index and Porter’s five force analysis for infertility (testing and treatment) market. Also, the trends in infertility (testing and treatment) market have been studied.

In North America, the fertility rate ranges from 1.25 to 3.02 children per woman in the year 2015. The rising use of contraceptive drugs is increasing the infertility rate rapidly in the region. At least 1 out of 10 married or in-union women globally is anticipated to have an unmet need for family planning which states that they are in great need of avoiding pregnancy, but they do not use any precautions. North America is minimally impacted due to the awareness regarding contraception precautions and several governmental policies for healthcare such as the affordable care act and so on. The rise in the use of numerous traditional and modern contraceptive drugs has raised concerns for infertility in the North American region.

According to SART (Society for Assisted Reproductive Technologies), out of total cycles performed, more than 99% have adopted IVF treatment. The adoption of other ART treatments such as GIFT and ZIFT is less than 1%. 67% of couples have adopted IVF with ICSI procedures. Major drivers surging the market growth is the awareness among people about various tests and treatments. Another reason for the growing number of IVF treatment is delayed pregnancies in American women. American women now prefer to have babies at later stages in life, as compared to earlier years. The average age of a new mom in 1980 was about 22; whereas, now the average age of a new mom is around 26, as per the CDC (Centers for Disease Control and Prevention).

 

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    INFERTILITY (TESTING AND TREATMENT) MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. KEY INSIGHTS

2.2.1.   IVF DOMINATES THE FEMALE TREATMENT MARKET

2.2.2.   OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET

2.3. PORTER’S FIVE FORCE ANALYSIS

2.3.1.   THREAT OF NEW ENTRANTS

2.3.2.   THREAT OF SUBSTITUTE

2.3.3.   BARGAINING POWER OF BUYERS

2.3.4.   BARGAINING POWER OF SUPPLIERS

2.3.5.   INTENSITY OF COMPETITIVE RIVALRY

2.4. KEY IMPACT ANALYSIS

2.4.1.   TREATMENT OPTIONS

2.4.2.   QUALITY OF MEDICAL PROCEDURES

2.4.3.   PRICE OF TREATMENTS

2.4.4.   SHIFT TOWARDS MEDICAL TOURISM

2.4.5.   REIMBURSEMENT

2.5. MARKET ATTRACTIVENESS INDEX

2.6. VENDOR SCORECARD

2.7. INDUSTRY COMPONENTS

2.7.1.   RAW MATERIAL PROCUREMENT

2.7.2.   MANUFACTURING

2.7.3.   SUPPLY LOGISTICS

2.7.4.   DISTRIBUTION CHANNELS

2.7.5.   END-USERS

2.8. REGULATORY FRAMEWORK

2.9. MARKET DRIVERS

2.9.1.   RISE IN INFERTILITY AND TREATMENT AWARENESS

2.9.2.   MEDICAL TOURISM IN FERTILITY TREATMENTS

2.9.3.   SURROGACY LAWS ARE GETTING MORE DEFINED

2.9.4.   HEALTHCARE ADVANCES HAVE FINE-TUNED FERTILITY TREATMENT

2.9.5.   INCREASING EFFECTIVENESS OF TREATMENTS

2.9.6.   HEALTHIER DONOR EGGS

2.9.7.   INTRODUCTION OF NEW TESTING DEVICES

2.10.            MARKET RESTRAINTS

2.10.1.                TREATMENT PROCEDURE OUT OF REACH FOR MANY DUE TO HIGH COSTS

2.10.2.                COUNTRY-WISE REGULATORY ISSUES

2.11.            MARKET OPPORTUNITIES

2.11.1.                REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE

2.11.2.                IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS

2.11.3.                DIY TESTING INCREASING ACCESS AND REDUCING COST

2.12.            MARKET CHALLENGES

2.12.1.                INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN

2.12.2.                PERILS OF MULTIPLE PREGNANCIES

2.12.3.                TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE FOR INFERTILITY TREATMENTS

3.    INFERTILITY (TESTING AND TREATMENT) MARKET OUTLOOK - BY GENDER

3.1. MALE GENDER

3.1.1.   TESTING

3.1.1.1.      DNA FRAGMENTATION

3.1.1.2.      OXIDATIVE STRESS ANALYSIS

3.1.1.3.      SPERM PENETRATION ASSAY

3.1.1.4.      COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)

3.1.1.5.      SPERM AGGLUTINATION

3.1.1.6.      MICROSCOPIC EXAMINATION

3.1.1.7.      OTHERS

3.1.2.   TREATMENT

3.2. FEMALE GENDER

3.2.1.   FEMALE INFERTILITY TESTING

3.2.1.1.      OVULATION TESTING

3.2.1.2.      HYSTEROSALPINGOGRAPHY

3.2.1.3.      LAPAROSCOPY

3.2.1.4.      TRANSVAGINAL ULTRASOUND

3.2.1.5.      OVARIAN RESERVE TESTING

3.2.1.6.      HORMONAL LEVEL TESTING

3.2.1.7.      OTHERS

3.2.2.   TREATMENT

4.    INFERTILITY (TESTING AND TREATMENT) MARKET OUTLOOK - BY END-USE

4.1. FERTILITY CLINICS

4.2. HOSPITALS

4.3. SURGICAL CENTERS

4.4. CLINICAL RESEARCH INSTITUTES

5.    INFERTILITY (TESTING AND TREATMENT) MARKET - REGIONAL OUTLOOK

5.1.      UNITED STATES

5.2.      CANADA

6.    COMPETITIVE LANDSCAPE

6.1. ANDROLOGY SOLUTIONS

6.2. ENDO PHARMACEUTICALS

6.3. PROGYNY

6.4. FERRING PHARMACEUTICALS

6.5. GENEA

6.6. HALOTECH DNA

6.7. IRVINE SCIENTIFIC

6.8. MERCK

6.9. ORIGIO

6.10.            OVASCIENCE

6.11.            VITROLIFE AB        

6.12.            THERMO FISHER SCIENTIFIC, INC.

6.13.            THE COOPER COMPANIES, INC.

6.14.            QUEST DIAGNOSTIC

6.15.            ESCO MICRO PTE. LTD.

7.    RESEARCH METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE & DELIVERABLES

7.1.1.   OBJECTIVES OF STUDY

7.2. SOURCES OF DATA

7.2.1.   PRIMARY DATA SOURCES

7.2.2.   SECONDARY DATA SOURCES

7.3. RESEARCH METHODOLOGY

7.3.1.   EVALUATION OF PROPOSED MARKET

7.3.2.   IDENTIFICATION OF DATA SOURCES

7.3.3.   ASSESSMENT OF MARKET DETERMINANTS

7.3.4.   DATA COLLECTION

7.3.5.   DATA VALIDATION & ANALYSIS

List of table

TABLE 1:       NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)

TABLE 2:       MARKET ATTRACTIVENESS INDEX

TABLE 3:       VENDOR SCORECARD

TABLE 4:       REGULATORY FRAMEWORK

TABLE 5:       AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS

TABLE 6:       NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)

TABLE 7:       NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY GENDER, 2019-2027 (IN $ MILLION)

TABLE 8:       NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY END-USE, 2019-2027 (IN $ MILLION)

TABLE 9:       NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY MALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)

TABLE 10:     NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE GENDER, 2019-2027 (IN $ MILLION)

TABLE 11:     NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)

TABLE 12:     NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY GENDER, 2019-2027 (IN $ MILLION)

TABLE 13:     SUCCESS OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) USING DONOR EGGS IN THE US IN 2013

TABLE 14:     COSTS FOR INFERTILITY TREATMENTS IN THE US 2015

TABLE 15:     COST OF IVF & ICSI TREATMENT, CANADA 2014

List of Figures

FIGURE 1:     NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY END-USER, 2018 & 2027 (IN %)

FIGURE 2:     PORTER’S FIVE FORCE ANALYSIS

FIGURE 3:     KEY BUYING IMPACT ANALYSIS

FIGURE 4:     INDUSTRY COMPONENTS

FIGURE 5:     MAJOR FERTILITY TREATMENT DESTINATION RANKING

FIGURE 6:     CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN

FIGURE 7:     RATE OF MULTIPLE DELIVERIES

FIGURE 8:     NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY MALE GENDER, 2019-2027 (IN $ MILLION)

FIGURE 9:     NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY TESTING, 2019-2027 (IN $ MILLION)

FIGURE 10:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY DNA FRAGMENTATION, 2019-2027 (IN $ MILLION)

FIGURE 11:  CAUSES OF SPERM DNA FRAGMENTATION

FIGURE 12:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY OXIDATIVE STRESS ANALYSIS, 2019-2027 (IN $ MILLION)

FIGURE 13:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY SPERM PENETRATION ASSAY, 2019-2027 (IN $ MILLION)

FIGURE 14:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY COMPUTER-ASSISTED SEMEN ANALYSIS, 2019-2027 (IN $ MILLION)

FIGURE 15:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY SPERM AGGLUTINATION, 2019-2027 (IN $ MILLION)

FIGURE 16:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY MICROSCOPIC EXAMINATION, 2019-2027 (IN $ MILLION)

FIGURE 17:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)

FIGURE 18:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY TREATMENT, 2019-2027 (IN $ MILLION)

FIGURE 19:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE GENDER, 2019-2027 (IN $ MILLION)

FIGURE 20:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)

FIGURE 21:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY OVULATION TESTING, 2019-2027 (IN $ MILLION)

FIGURE 22:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY HYSTEROSALPINGOGRAPHY, 2019-2027 (IN $ MILLION)

FIGURE 23:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY LAPAROSCOPY, 2019-2027 (IN $ MILLION)

FIGURE 24:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY TRANSVAGINAL ULTRASOUND, 2019-2027 (IN $ MILLION)

FIGURE 25:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY OVARIAN RESERVE TESTING, 2019-2027 (IN $ MILLION)

FIGURE 26:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY HORMONAL LEVEL TESTING, 2019-2027 (IN $ MILLION)

FIGURE 27:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)

FIGURE 28:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TREATMENT, 2019-2027 (IN $ MILLION)

FIGURE 29:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY FERTILITY CLINICS, 2019-2027 (IN $ MILLION)

FIGURE 30:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY HOSPITALS, 2019-2027 (IN $ MILLION)

FIGURE 31:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY SURGICAL CENTERS, 2019-2027 (IN $ MILLION)

FIGURE 32:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, BY CLINICAL RESEARCH INSTITUTES, 2019-2027 (IN $ MILLION)

FIGURE 33:  NORTH AMERICA INFERTILITY (TESTING AND TREATMENT) MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)

FIGURE 34:  UNITED STATES INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 35:  CANADA INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;